Johnson & Johnson (JNJ) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for JNJ is $273.93 — 8.3% above the latest price of $253.02.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for JNJ is supported by its diversified business model, strong performance in its Innovative Medicine and MedTech segments, and a robust product pipeline. Key growth drivers include blockbuster therapies like Darzalex and Tremfya, with several new indications and approvals anticipated. The company's raised full-year guidance and ongoing investments in R&D, including the Shockwave SkyRunner Carotid IVL system and the OTTAVA robotic system, are expected to fuel future growth. JNJ's defensive characteristics, consistent earnings, and status as a Dividend King make it an attractive long-term holding, especially amidst market volatility. Strategic acquisitions, such as Firefly Bio and Expanding Innovations, also contribute to its growth trajectory.
Bear Case
The bear case for JNJ centers on potential headwinds such as the patent cliff for high-revenue pharmaceutical products like STELARA, which has already seen a significant decline in sales due to biosimilar competition. Ongoing talc litigation represents a significant financial and reputational risk. The competitive landscape in key therapeutic areas like oncology and immunology could pressure future growth and profitability. Additionally, potential changes to healthcare reimbursement policies and ongoing supply chain volatility could impact manufacturing costs and overall performance. Morningstar recently downgraded JNJ to a 1-star (overvalued) rating, flagging it as trading at a 34% premium to its $190 fair value estimate, suggesting potential overvaluation.
Model-assessed risk level: Low
Key Catalysts to Watch
Upcoming regulatory and clinical milestones in oncology, immunology, neuroscience, and MedTech.
Expected approval and market penetration of the OTTAVA robotic system.
Label expansion opportunities for key drugs such as Tremfya, Icotyde, Caplyta, and nipocalimab.
Strategic acquisitions and partnerships.
Continued strong performance and new launches in the Innovative Medicine and MedTech segments.
Technical Backdrop
RSI-14
53.1
50-Day MA
$246.20
200-Day MA
$204.78
From 52-Wk High
-5.3%
Full momentum breakdown: Is JNJ overbought or oversold?
Model Notes
Johnson & Johnson (JNJ) is a diversified global healthcare giant with a strong presence in Innovative Medicine and MedTech. The company recently reported robust Q2 2026 results, surpassing revenue and EPS estimates, and subsequently raised its full-year guidance, projecting to exceed $100 billion in annual revenue for the first time in its history. JNJ is recognized as a Dividend King, consistently increasing its dividend for over six decades, underpinned by strong cash flows and a solid balance sheet. While facing challenges such as patent expirations for key drugs and ongoing talc litigation, its extensive pipeline, strategic acquisitions, and focus on high-growth therapeutic areas position it for continued stability and growth.
JNJ stock closed at $252.45 on Friday, July 17th, reflecting a 1.14% increase from the previous trading session. Over the past 24 hours, the stock increased by 1.19%. While it experienced a -4.09% decline over the past week, it has risen 5.75% in the last month and demonstrated a significant 56.01% increase over the last year. The stock reached an all-time high of $269.43 on July 6, 2026. A recent post-earnings pullback is viewed by some analysts as a buying opportunity, indicating potential for a rebound. JNJ's beta coefficient of -0.41 suggests lower volatility compared to the broader market.
Current Street Context
July 16, 2026The AI price target for Johnson & Johnson is $273.93. Analyst sentiment for JNJ is generally positive, with a consensus rating of 'Buy' from 19 analysts, including 32% recommending 'Strong Buy' and 32% 'Buy'. TipRanks indicates an average analyst price target of $273.93, with a high forecast of $300.00 and a low of $255.00. Recent analyst ratings from firms like TD Cowen, RBC Capital, and B of A Securities in mid-July 2026 also suggest potential upside. The company is expected to release its Q3 2026 earnings report on October 13, 2026, with analysts projecting an EPS of $3.02. Key factors influencing future performance include the company's ongoing M&A activities, litigations, and new product launches within the healthcare sector. Price targets are estimates and not guaranteed outcomes.
Frequently Asked Questions
What is the price target for JNJ?
How is this forecast generated?
How accurate are stock price predictions?
Will JNJ stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews JNJ’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on JNJ
Johnson & Johnson Overview
Price, chart, analysis & financials
JNJ: Overbought or Oversold?
Updated daily
JNJ: Why Is It Moving?
Updated daily
JNJ: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers